The company will work towards increasing volumes in the gastro-intestinal, anti-diabetic and cardio segments, among others, to overcome margin pressures due to industry headwinds, says Prabhat Agrawal, CEO of Alkem Laboratories.
first published: May 30, 2016 09:27 am
A collection of the most-viewed Moneycontrol videos.
Live: Sensex, Nifty rangebound on monthly expiry day | Closing Bell
Live: Will Nifty's downtrend continue to third session on expiry day? | Opening Bell
Nifty Slips Below 26,100 Amid Sluggish Trade, Midcaps Struggle; IT Lends Support | Closing Bell Live
Live: Can Nifty reach its all-time high levels this week? | Opening Bell
